Introduction
============

Targeted therapies in thoracic oncology are starting to compete with 'classic' chemotherapies due to their better clinical tolerance and easier mode of administration. However, we are now faced with a new complication because of their increased usage. Tyrosine kinase inhibitors (TKIs) are now widely prescribed in thoracic oncology: thus, managing any toxicity should be optimal to improve adherence. Here we report a case in which erlotinib caused transformation of pulmonary nodules into cysts; this has not been described previously in the literature.

Case presentation
=================

A 35-year-old Caucasian woman and former cigarette smoker presented with dyspnea and neck pain. A computed tomography (CT) scan revealed bilateral round opacities in both lungs (Figure [1](#F1){ref-type="fig"}A, C), hepatic metastases, osteolysis of her second cervical vertebra (C2) (Figure [2](#F2){ref-type="fig"}A), and two cerebral metastases. A percutaneous biopsy of the hepatic metastasis showed lung adenocarcinoma with a deletion in the epidermal growth factor receptor exon 19 (del E746-A750).Treatment with erlotinib was started. After 2 months she was hospitalized in our intensive care unit for an acute respiratory distress syndrome, secondary to a bilateral and spontaneous pneumothorax, which required placement of a chest tube. A thoracic CT scan revealed the replacement of diffuse parenchymatous nodules by cystic lesions (Figure [1](#F1){ref-type="fig"}B, D). Because of prolonged air leakage but also a good response to oncological treatment, a two-stage thoracoscopic bilateral talc poudrage was performed. Her postoperative course was uneventful and the drains were removed at 3 weeks after surgery.

![**Thoracic computed tomography scan. (A) (C)** Initial thoracic computed tomography scan showing multiple pulmonary metastases. **(B) (D)** Thoracic computed tomography scan after 2 months of treatment with erlotinib, showing a partial thoracic response with the appearance of pulmonary cysts and a partially drained bilateral pneumothorax.](1752-1947-8-335-1){#F1}

![**Computed tomography scan of the neck. (A)** revealing C2 osteolysis as indicated by the arrow. **(B)** showing osteocondensation (as indicated by the arrow) in the location of the initial lysis of the C2 vertebrae after 2 months of treatment with erlotinib.](1752-1947-8-335-2){#F2}

The cancer progressed within the next 9 months. A second-line treatment of cisplatin, pemetrexed, and bevacizumab followed by a maintenance therapy of bevacizumab, was given. After 6 months of chemotherapy, the tumor had progressed and erlotinib was reintroduced. This therapy was associated with a cerebral infarction in the context of paraneoplastic syndrome. The patient died 18 months later from disease progression.

Discussion
==========

In this patient, erlotinib gave an excellent initial response; there was complete disappearance of the cerebral metastases, and the osteocondensation of the C2 vertebrae (Figure [2](#F2){ref-type="fig"}B). However, lysis of the subpleural metastases (Figure [1](#F1){ref-type="fig"}B, C) could explain the occurrence of the cystic lesions and pneumothorax.

We have recently reported a case in which there was transformation of pulmonary nodules into pulmonary cysts in a 40-year-old woman who was a non-cigarette smoker with multi-metastatic pulmonary adenocarcinoma, an *EML4-ALK* gene rearrangement, and who was successfully treated with crizotinib \[[@B1]\].

The phenomenon of cyst formation is caused by parenchymal necrosis as a result of targeted therapy, but which also increases the risk of a pneumothorax. Tumor necrosis has previously been described in connection with the lysis of some chemosensitive tumors, such as germinal tumors, lymphomas, and sarcomas \[[@B2],[@B3]\], with a 1% risk of a pneumothorax occurring within 2 to 7 days following the start of chemotherapy \[[@B4]\].

Transformation of tumor lesions into cysts is also a difficulty in Response Evaluation Criteria in Solid Tumours assessments. The solid tumors initially retain the same diameter as the newly formed cysts.

TKIs are prescribed as a first-line therapy in the context of sensitive mutations, and produce a response rate of 50 to 90% and progression-free survival times of 9.7 to 13.1 months; this is compared to 4.6 to 5.2 months in patients treated with a platinum-based chemotherapy \[[@B5]\].

Here we report the unusual response of the lung after erlotinib therapy, in which the lung nodules were transformed into cysts via a mechanism that was probably associated with necrosis.

Conclusions
===========

The association between lysis of a lung tumor and its replacement by a cyst seemed to be caused by erlotinib treatment: thus, this should be borne in mind, as the rupture of a cyst in the pleura can result in a life-threatening pneumothorax.
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